Acute Effects of Insulin-like Growth Factor I on Interorgan Glucose and Lactate Flux in Protein-Catabolic Dogs

Luzia Valentini, Thomas Hözenbein, Susanne Winkler, Thomas Sautner, Günther Ollenschläger, Heide Hötnagl, J. Karner, Erich Roth

Research output: Article

3 Citations (Scopus)

Abstract

Insulin-like growth factor-I (IGF-I) is a potent protein-anabolic hormone with a glucose-lowering effect and is therefore a possible agent for treating catabolic patients. In this study we investigated the effect of recombinant human (rh) IGF-I on the interorgan flux of glucose under hypo- and normoglycemic conditions in catabolic, anaesthetized, and catheterized dogs. We administered a primed (40 μg/kg) continuous (1.5 μg · kg-1 · min-1) infusion of rhIGF-I (Kabi Biopharma, Stockholm, Sweden) for 180 min together with either a saline (0.9% NaCl) or an amino acid solution (2.2 mg AA · kg-1 · min-1 solution of Vamin, Kabi Nutrition, Stockholm, Sweden). RhIGF-I administration lowered plasma glucose levels for approximately 50% of the baseline (P <0.001) and stimulated glucose uptake from skeletal muscle about twofold (P <0.01), but did not modify glucose balances across the gut and liver. The same effects were found when infusing rhIGF-I together with AA. A co-infusion of rhIGF-I and glucose to maintain normoglycemic conditions stimulated glucose uptake from skeletal muscle by about fivefold (P <0.001) and glucose uptake across the gut by about 50%, but reduced the hepatic glucose liberation (-65%; P <0.01). The rhIGF-I infusion did not alter arterial lactate levels, but stimulated lactate release from skeletal muscle (P <0.05) and lactate uptake across the liver (P <0.05). We conclude that rhIGF-I reduces plasma glucose levels mainly by stimulating glucose uptake across skeletal muscle. Because muscular glucose uptake was higher than lactate release, rhIGF-I possibly stimulated glycogen synthesis or ATP formation in skeletal muscle and therefore may have positive effects on the peripheral energy deficit in catabolic state.

Original languageEnglish
Pages (from-to)606-613
Number of pages8
JournalJournal of Surgical Research
Volume59
Issue number5
DOIs
Publication statusPublished - nov. 1995

Fingerprint

Insulin-Like Growth Factor I
Lactic Acid
Dogs
Glucose
Proteins
Skeletal Muscle
Sweden
Liver
Glycogen
Hypoglycemic Agents
Adenosine Triphosphate
Hormones
Amino Acids

ASJC Scopus subject areas

  • Surgery

Cite this

Valentini, L., Hözenbein, T., Winkler, S., Sautner, T., Ollenschläger, G., Hötnagl, H., ... Roth, E. (1995). Acute Effects of Insulin-like Growth Factor I on Interorgan Glucose and Lactate Flux in Protein-Catabolic Dogs. Journal of Surgical Research, 59(5), 606-613. https://doi.org/10.1006/jsre.1995.1212

Acute Effects of Insulin-like Growth Factor I on Interorgan Glucose and Lactate Flux in Protein-Catabolic Dogs. / Valentini, Luzia; Hözenbein, Thomas; Winkler, Susanne; Sautner, Thomas; Ollenschläger, Günther; Hötnagl, Heide; Karner, J.; Roth, Erich.

In: Journal of Surgical Research, Vol. 59, No. 5, 11.1995, p. 606-613.

Research output: Article

Valentini, L, Hözenbein, T, Winkler, S, Sautner, T, Ollenschläger, G, Hötnagl, H, Karner, J & Roth, E 1995, 'Acute Effects of Insulin-like Growth Factor I on Interorgan Glucose and Lactate Flux in Protein-Catabolic Dogs', Journal of Surgical Research, vol. 59, no. 5, pp. 606-613. https://doi.org/10.1006/jsre.1995.1212
Valentini, Luzia ; Hözenbein, Thomas ; Winkler, Susanne ; Sautner, Thomas ; Ollenschläger, Günther ; Hötnagl, Heide ; Karner, J. ; Roth, Erich. / Acute Effects of Insulin-like Growth Factor I on Interorgan Glucose and Lactate Flux in Protein-Catabolic Dogs. In: Journal of Surgical Research. 1995 ; Vol. 59, No. 5. pp. 606-613.
@article{f8055c5729e34efd863cc4ca3c2c0ed4,
title = "Acute Effects of Insulin-like Growth Factor I on Interorgan Glucose and Lactate Flux in Protein-Catabolic Dogs",
abstract = "Insulin-like growth factor-I (IGF-I) is a potent protein-anabolic hormone with a glucose-lowering effect and is therefore a possible agent for treating catabolic patients. In this study we investigated the effect of recombinant human (rh) IGF-I on the interorgan flux of glucose under hypo- and normoglycemic conditions in catabolic, anaesthetized, and catheterized dogs. We administered a primed (40 μg/kg) continuous (1.5 μg · kg-1 · min-1) infusion of rhIGF-I (Kabi Biopharma, Stockholm, Sweden) for 180 min together with either a saline (0.9{\%} NaCl) or an amino acid solution (2.2 mg AA · kg-1 · min-1 solution of Vamin, Kabi Nutrition, Stockholm, Sweden). RhIGF-I administration lowered plasma glucose levels for approximately 50{\%} of the baseline (P <0.001) and stimulated glucose uptake from skeletal muscle about twofold (P <0.01), but did not modify glucose balances across the gut and liver. The same effects were found when infusing rhIGF-I together with AA. A co-infusion of rhIGF-I and glucose to maintain normoglycemic conditions stimulated glucose uptake from skeletal muscle by about fivefold (P <0.001) and glucose uptake across the gut by about 50{\%}, but reduced the hepatic glucose liberation (-65{\%}; P <0.01). The rhIGF-I infusion did not alter arterial lactate levels, but stimulated lactate release from skeletal muscle (P <0.05) and lactate uptake across the liver (P <0.05). We conclude that rhIGF-I reduces plasma glucose levels mainly by stimulating glucose uptake across skeletal muscle. Because muscular glucose uptake was higher than lactate release, rhIGF-I possibly stimulated glycogen synthesis or ATP formation in skeletal muscle and therefore may have positive effects on the peripheral energy deficit in catabolic state.",
author = "Luzia Valentini and Thomas H{\"o}zenbein and Susanne Winkler and Thomas Sautner and G{\"u}nther Ollenschl{\"a}ger and Heide H{\"o}tnagl and J. Karner and Erich Roth",
year = "1995",
month = "11",
doi = "10.1006/jsre.1995.1212",
language = "English",
volume = "59",
pages = "606--613",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "5",

}

TY - JOUR

T1 - Acute Effects of Insulin-like Growth Factor I on Interorgan Glucose and Lactate Flux in Protein-Catabolic Dogs

AU - Valentini, Luzia

AU - Hözenbein, Thomas

AU - Winkler, Susanne

AU - Sautner, Thomas

AU - Ollenschläger, Günther

AU - Hötnagl, Heide

AU - Karner, J.

AU - Roth, Erich

PY - 1995/11

Y1 - 1995/11

N2 - Insulin-like growth factor-I (IGF-I) is a potent protein-anabolic hormone with a glucose-lowering effect and is therefore a possible agent for treating catabolic patients. In this study we investigated the effect of recombinant human (rh) IGF-I on the interorgan flux of glucose under hypo- and normoglycemic conditions in catabolic, anaesthetized, and catheterized dogs. We administered a primed (40 μg/kg) continuous (1.5 μg · kg-1 · min-1) infusion of rhIGF-I (Kabi Biopharma, Stockholm, Sweden) for 180 min together with either a saline (0.9% NaCl) or an amino acid solution (2.2 mg AA · kg-1 · min-1 solution of Vamin, Kabi Nutrition, Stockholm, Sweden). RhIGF-I administration lowered plasma glucose levels for approximately 50% of the baseline (P <0.001) and stimulated glucose uptake from skeletal muscle about twofold (P <0.01), but did not modify glucose balances across the gut and liver. The same effects were found when infusing rhIGF-I together with AA. A co-infusion of rhIGF-I and glucose to maintain normoglycemic conditions stimulated glucose uptake from skeletal muscle by about fivefold (P <0.001) and glucose uptake across the gut by about 50%, but reduced the hepatic glucose liberation (-65%; P <0.01). The rhIGF-I infusion did not alter arterial lactate levels, but stimulated lactate release from skeletal muscle (P <0.05) and lactate uptake across the liver (P <0.05). We conclude that rhIGF-I reduces plasma glucose levels mainly by stimulating glucose uptake across skeletal muscle. Because muscular glucose uptake was higher than lactate release, rhIGF-I possibly stimulated glycogen synthesis or ATP formation in skeletal muscle and therefore may have positive effects on the peripheral energy deficit in catabolic state.

AB - Insulin-like growth factor-I (IGF-I) is a potent protein-anabolic hormone with a glucose-lowering effect and is therefore a possible agent for treating catabolic patients. In this study we investigated the effect of recombinant human (rh) IGF-I on the interorgan flux of glucose under hypo- and normoglycemic conditions in catabolic, anaesthetized, and catheterized dogs. We administered a primed (40 μg/kg) continuous (1.5 μg · kg-1 · min-1) infusion of rhIGF-I (Kabi Biopharma, Stockholm, Sweden) for 180 min together with either a saline (0.9% NaCl) or an amino acid solution (2.2 mg AA · kg-1 · min-1 solution of Vamin, Kabi Nutrition, Stockholm, Sweden). RhIGF-I administration lowered plasma glucose levels for approximately 50% of the baseline (P <0.001) and stimulated glucose uptake from skeletal muscle about twofold (P <0.01), but did not modify glucose balances across the gut and liver. The same effects were found when infusing rhIGF-I together with AA. A co-infusion of rhIGF-I and glucose to maintain normoglycemic conditions stimulated glucose uptake from skeletal muscle by about fivefold (P <0.001) and glucose uptake across the gut by about 50%, but reduced the hepatic glucose liberation (-65%; P <0.01). The rhIGF-I infusion did not alter arterial lactate levels, but stimulated lactate release from skeletal muscle (P <0.05) and lactate uptake across the liver (P <0.05). We conclude that rhIGF-I reduces plasma glucose levels mainly by stimulating glucose uptake across skeletal muscle. Because muscular glucose uptake was higher than lactate release, rhIGF-I possibly stimulated glycogen synthesis or ATP formation in skeletal muscle and therefore may have positive effects on the peripheral energy deficit in catabolic state.

UR - http://www.scopus.com/inward/record.url?scp=0028819770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028819770&partnerID=8YFLogxK

U2 - 10.1006/jsre.1995.1212

DO - 10.1006/jsre.1995.1212

M3 - Article

C2 - 7475008

AN - SCOPUS:0028819770

VL - 59

SP - 606

EP - 613

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 5

ER -